| Literature DB >> 20572799 |
André Goy1, Steven H Bernstein, Alice McDonald, Michael D Pickard, Hongliang Shi, Mark D Fleming, Barb Bryant, William Trepicchio, Richard I Fisher, Anthony L Boral, George Mulligan.
Abstract
Immunohistochemical analyses of archival tumor specimens were used for pre-planned exploratory analyses of protocol-specified candidate biomarkers of bortezomib activity in 73 patients with relapsed/refractory mantle cell lymphoma in the phase 2 PINNACLE study. Consistent with other studies, elevated Ki-67 was a marker of poor prognosis, demonstrating significant associations with shorter time to progression and overall survival. Elevated NF-kappaB p65 and low PSMA5 expression demonstrated a trend for better response and were significantly associated with longer time to progression; elevated NF-kappaB p65 demonstrated a trend toward longer overall survival. This is consistent with myeloma clinical genomics research, suggesting biomarker relevance across tumor types. Elevated p27 was significantly associated with longer overall survival. Overall survival analyses by International Prognostic Index and Mantle Cell Lymphoma International Prognostic Index confirmed differential prognosis by both scores. These biomarkers data begin to illuminate bortezomib's mechanism of action in lymphoma.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20572799 DOI： 10.3109/10428194.2010.483302
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022